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expression of GRK2 and BCAR3 has modest effects on decreasing TGFβ-induced transcription from 12CAGA-lux, a Smad-responsive artificial reporter gene (data not shown). This is likely due to the low level of expression of these factors. To obtain cell lines that allow us to conduct in vivo experiments, we have constructed viral vectors for inducible expression of GRK2 and BCAR3 in human breast cancer cells. To do so we have subcloned Flag-tagged human GRK2 or BCAR3 open reading frames into pLVX-TRE3G lentiviral vector, produced viral particles, infected SUM-159 cells and recently established pools of cells resistance to antibiotic selection. We are currently validating inducible expression of GRK2 or BCAR3 by Western blot and Immunofluorescence.
Task 2: Evaluate the effects of BCAR3 on Smad signaling and TGFβ-induced cell invasion.
In previous funding years, we found that BCAR3 is an endogenous factor in breast cancer cells that antagonizes Smad activation. We further tested whether overexpressing BCAR3 could impair Smad-mediated transcriptional responses. We found that BCAR3 overexpression could effectively block TGFβ-induced Smad nuclear translocation and Smad-dependent transcription (please see previous reports and manuscript/Appendix A). TGFβ induces cell migration and invasion in basal-like metastastatic breast cancer cells, such as MDA-MB-231 cells and SCP2 cells. We opted for a real time live cell imaging approach and found that knocking down endogenous BCAR3 in SCP2 cells promoted TGFβ-induced cell migration (please see attached manuscript). Moreover, knocking down BCAR3 in SCP2 cells resulted in remarkable increases in TGFβ-induced cell invasion through matrigel (Figure 1/Appendix B) . We also obtained similar results using another basal-like breast cancer cell line, BT-549 cells. These results suggest that endogenous BCAR3 is an antagonistic mechanism of TGFβ's pro-invasive responses. In addition to the transwell experiments proposed in the SOW, we also used a gelatin matrix degradation assay to study cell invasion, as this method allows us to visualize single cell invasion and morphology of invadopodia. In MDA-MB-231 cells, TGFβ remolded invadopodia structure, from a scattered pattern to a bundled pattern that favors cell invasion. Knocking down BCAR3 facilitated this response, and increased both invadopodia number and total area of digestion in response to TGFβ (please see manuscript/Appendix A).
Task 3. Evaluate the effects of ectopic GRK2 in antagonizing metastasis in vivo.
As discussed in Task 1, we experienced technical difficulty generating stable cell lines that could express ideal levels of GRK2 for in vivo studies. To conduct the proposed in vivo studies, we are currently selecting viral-infected SUM-159 cells for inducible GRK2 expression. At the main time, we addressed this task using the matrix degradation assay as described in Task 2. We transfected FLAG-tagged GRK2 into MDA-MB-231 cells, allowed cells to invade into gelatin matrix for 48 hours, and then observe the effect of ectopic GRK2 on matrix degradation. Under these conditions, we observed that under each cell there were black dots joining into large areas, representing degradation of fluorescence gelatin matrix. However, this effect seemed to be absent in cells expressing FLAG-tagged GRK2 (Figure 2/Appendix B) . Furthermore, we also found that ectopic GRK2 expression in MDA-MB-231 cells could block TGFβ-induced matrix degradation ( Figure 2/Appendix B) . This result serves as a proof-of-principle for our proposed in vivo experiments, which we will conduct as soon as we obtain the stable inducible cells.
Task 4. Training.
With the support of the traineeship, I have attended several courses, training workshops and conferences, as listed in previous annual reports. During the past year, I have attended a symposium hosted by NIH's Integrative Network-Based Cellular Signature program and a symposium hosted by the Cancer Center of Beth Israel Deaconess Medical Center, in Boston MA and on consecutive dates. These events extend my scope of knowledge on Systems Biology and Cancer Biology, respectively. In particular, they further shaped my research interest on breast cancer, to studying mechanisms that influence drug responses and prognosis using genomic and proteomic approaches. During the tenure of the traineeship, I prepared a first author manuscript reporting the novel role of BCAR3 as an antagonistic factor of Smad signaling. It is currently under peer review. I also contributed to a few manuscripts; two of which are published and one is under peer review (Appendix C). 
Key Research Accomplishments

Appendix:
A. Manuscript entitled "Breast Cancer Anti-Estrogen Resistance-3 (BCAR3) inhibits TGFbeta/Smad signaling and associates with favorable breast cancer disease outcomes". B. Figure 1 and In this study, we investigated the role of the Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) gene in breast cancer progression. Our results define a novel function for BCAR3 as a potent inhibitor of the TGFβ signaling pathway. We found BCAR3 to inhibit Smad activation, Smad-mediated gene transcription, Smad-dependent cell migration and matrix digestion in breast cancer cells. Furthermore, we found BCAR3 gene expression itself to be repressed by TGFβ, defining a novel positive feedback loop mechanism downstream of the TGFβ/Smad signaling pathway. Examination of BCAR3 expression levels in large cohorts of breast cancer patients also indicate that BCAR3 bears a true prognostic value in human breast cancer. Indeed, loss of BCAR3 expression in primary breast tumors correlates with distant metastasis free survival (DMFS) and relapse free survival (RFS) poor outcomes, regardless of molecular subtype and treatment.
We also found a strong correlation between the loss of BCAR3 expression and lymph node invasion in human breast cancer, further suggesting a role for BCAR3 in preventing disease progression. Traditionally, BCAR3 has been considered to be associated with aggressive breast cancer phenotypes. However, our results indicate that BCAR3 acts as a putative suppressor of breast cancer progression by inhibiting the pro-metastatic TGFβ/Smad signaling pathway in invasive breast tumors. These data provides new insights into BCAR3's molecular mechanism of action and highlight BCAR3 as a novel TGFβ/Smad antagonist in breast cancer.
Keywords: BCAR3, TGFβ, Smad, migration, invasion, breast cancer prognosis
Introduction:
Breast tumorigenesis and progression are controlled by multiple hormone/growth factor/cytokine signaling pathways, which are ideal therapeutic targets. Targeted therapies against breast cancer, such as those developed towards the Estrogen Receptor alpha (ERα) or the Her2 receptor tyrosine kinase, have shown some levels of success 1,2 .
However, clinical observations also indicate that tumors which initially respond to targeted therapies often relapse and acquire resistance to the treatments 3, 4 . Several genes, collectively named Breast Cancer Anti-Estrogen Resistance (BCAR) genes were found to induce estrogen-independent cell growth in estrogen-dependent breast cancer cells 5 . Two members, BCAR1/p130Cas and BCAR3 are found to form a complex by directly interacting with each other 6, 7 . Individual overexpression of these genes allows estrogendependent breast cancer cells to proliferate under the presence of Tamoxifen 5, 8 . Ectopic overexpression of BCAR3 in breast cancer cells activate Src and FAK kinases, leading to p130Cas tyrosine phosphorylation and increased cell attachment to fibronectin and cell motility 7, 9 . Therefore, BCAR3 is traditionally considered to play a role in mediating aggressive breast cancer phenotype. However, a previous report suggested BCAR3 expression to correlate with favorable outcome in progression free survival in a cohort of estrogen receptor positive breast cancer patients who had received Tamoxifen 10 . As such, the regulatory role played by BCAR3 in breast cancer cells remained unclear and controversial and is aimed to be addressed in this study.
During breast cancer progression, alongside the development of hormone-independent growth mechanisms, cancer cells have been shown to alter their biological response to the transforming growth factor β (TGFβ) 11 . TGFβ family growth factors, through inducing cell cycle arrest and apoptosis, inhibit proliferation in the mammary epithelium and in well-differentiated, early stage breast tumors [12] [13] [14] [15] . These functions are lost and replaced by tumor promoting and pro-metastatic responses in poorly-differentiated, advanced stage breast tumors 16, 17, 18, 19 . In cancer cells representing such tumors, TGFβ transcriptionally reprograms cells to induce epithelial to mesenchymal transition (EMT), cell migration and invasion 19, 2019 . In addition, in the stroma, TGFβ promotes local and systematic immune suppression, thereby allowing transformed cells to escape immune surveillance, further promoting tumor metastasis 19, 21, 22 . Most of the above mentioned biological functions of TGFβ are attributed to a canonical signaling pathway mediated by the Smad transcription factors 23 . TGFβ binding to its receptors (type I and type II serine threonine kinases) leads to the recruitment and phosphorylation of Smad2/3 and their association with Smad4. The activated Smads then collectively translocate into the nucleus where they bind to regulatory elements on the promoter regions of their target genes to regulate gene transcription 24 . The canonical TGFβ/Smad signaling axis is central to TGFβ-mediated breast cancer cell migration and tumor metastasis. Altering the function of key components of the TGFβ/Smad signaling, using RNA interference or decoy ligand traps approaches, impairs formation of breast cancer metastasis in experimental models 16, 25, 26 . As such, understanding how intracellular mechanisms regulate Smad signaling provides insights into the biology of metastatic breast cancer and novel means of treatment and prognosis.
In this study, we define a novel regulatory pathway directly linking the TGFβ/Smad signaling axis to BCAR3. Our data highlight BCAR3 as a potent inhibitor of the TGFβ/Smad signaling pathway. We found BCAR3 to promote an interaction between Smad2/3 and p130Cas, leading to inhibition of Smad activation, Smad-mediated gene transcription and Smad-dependent cell migration in breast cancer cells. Interestingly, we also found BCAR3 expression to be controlled by TGFβ itself, as TGFβ treatment decreases BCAR3 expression in a Smad-dependent manner. This define a novel positive regulatory feedback loop, through which TGFβ signaling further induces its effects by blocking expression of the Smad inhibitor, BCAR3. We also report a true prognostic value of BCAR3 in human breast cancer. We found that loss of BCAR3 expression in primary breast tumors correlates with poor outcomes, regardless of molecular subtype and treatment. Taken together, our study indicates that BCAR3 is a novel antagonist of TGFβ functions in breast cancer cells, and loss of BCAR3 function correlates with poor outcomes in breast cancer patients.
Methods:
Gene expression analysis: Using GOBO, patient outcomes were quarried for 10 years.
Compiled cohorts of patients were divided as described in the text, based on reading from an Affymetrix BCAR3 probe on microarrays (204032_at). In the analysis of endocrine treated patients, log rank readings from the probe targeting BCAR3 were extracted from the NCBI-GEO dataset GDS807, and plotted. SDS-PAGE and Western blot: Cells were lysed with RIPA buffer containing 1% Triton-X, protease inhibitors and phosphatase inhibitors. Total protein lysates were quantified and 50 µg lysates were separated by SDS-PAGE followed by transferring onto nitrocellulous membrane and subjected for Western blot as previously described. To obtain nuclear extracts, cells were lysed with PBS containing 1% NP-40. The nucleus were washed in the lysis buffer for multiple times and lysed with loading dye containing SDS, as described in a protocol described by the others. Confocal microscopy: Cells transfected with FLAG-AND-34 were seeded on cover slips, treated as described in figure legends, fixed with 3.7% paraformaldehyde in PBS for 15 minutes, and then permeabilized with 0.1% triton-X in PBS for 3 minutes. After blocking for 1 hour at room temperature in 2% BSA in PBS, cells were co-stained with a mouse anti-FLAG antibody (#M2, Sigma, 1:500) and a rabbit anti-phospho-Smad3 antibody (#9520, Cell Signaling, 1:500), or Alexa568-labled Phalloidin (Life Technologies). Cells were then stained with Alexa488-labled goat-anti-mouse secondary antibody (Life Technologies, 1:500) and Alexa568-labled goat-anti-rabbit secondary antibody (Life Technologies, 1:500), except in the case when Phalloidin used. Following DAPI counterstaining and mounting, images were taken using a X63 immersion oil objective on an LSM780 confocal microscope (Carl Zeiss). Images were taken in a multi-track scanning mode at a 1024X1024 resolution. Excitation wavelengths were set at 490nM (Argon laser) and 570nM (HeNe laser) for detecting emission wavelengths at around 520nM (for Alexa-488) and around 600nM (for Alexa-568), respectively. Images were converted to 16-bit TIFF RGB format by ImageJ. Images of individual channels were converted to grey scale, and merged images were set at auto-contrast using Photoshop CS6. Quantifications of phospho-Smad levels were performed using ImageJ software (5 images per condition).
Migration Assay: Scratch-based migration assays were carried out with an Incucyte automatic system (Essen Bioscience) according to the manufacturer's protocol. Briefly, cells transfected with siRNA were seeded onto I96-well ImageLock plate one day posttransfection at a density of 50,000 cells per well. Cells were then starved overnight.
Monolayers of cells were scratched using a scratching apparatus that produced highly identical scratches in each well. Cells were then treated with 100pM TGFβ. 
Results:
1. BCAR3 expression correlates with favorable breast cancer disease outcome.
BCAR3 is considered to be associated with aggressive disease phenotypes as it promotes estrogen-independent cell proliferation, cell migration, and cell-ECM contacts 5, 7, 9, 27, 28 .
However, a clinical study suggests BCAR3 expression to be a single factor to predict favorable progression-free survival of patients who received Tamoxifen treatment 10 . To investigate BCAR3's clinical implications, we used Gene Expression-Based Outcome for Breast Cancer Online (GOBO) 29 to generate Kaplan-Meier survival curves of breast cancer patients from published microarray datasets in the NCBI Genome Omnibus.
Consistent with the above mentioned study 10 , we found some level of correlation (p=0.09, data not shown) between high BCAR3 expression and low rate of disease progression in Tamoxifen-treated patient. More importantly, we extended our study to examine progression-free survival (PFS) to two distinct cohorts of patients: a compiled cohort that underwent various treatment plans and a true-prognostic cohort that received no systematic therapy. As shown in Fig.1A , in the compiled cohort, we found that those with low BCAR3 expression (grey) had significantly worse prognosis compared to patients with high BCAR3 levels (red), indicating that BCAR3 expression favors progression-free survival for patients who received various treatment plans. We also found a similar trend in non-treated patient cohort (Fig. 1B) . This not only demonstrates a true prognostic value for BCAR3, but also implicates that loss of BCAR3 expression may be involved in breast cancer progression. We further analyzed and correlated BCAR3 expression levels with distant metastasis or disease relapses. Consistently, we found BCAR3 expression to positively correlate with higher distant metastasis free survival (DMFS) in both an overall cohort and a non-treated cohort of patients ( Fig. 1C and 1D , respectively). Furthermore, BCAR3 expression also correlated with higher relapse free survival (RFS) in the overall cohort ( Fig. 1E ). In the non-treated cohort, when patients are separated by median expression level, no significant link is observed between BCAR3 and RFS (data not shown). However, when patients are separated into more refined groups, we found that the group that expressed the lowest level of BCAR3 had significant worse prognosis, whereas risks of the 4 other groups were comparable (Fig. 1F ). This suggests a dosedependent like effect of BCAR3, whereas a slight decrease of BCAR3 expression may not be detrimental to relapse-free survival, a severe loss of BCAR3 expression correlates with markedly increased tumor relapse.
Complimentary to these findings, we further investigated whether established disease characteristics can be traced backwards to BCAR3 expression levels in primary breast tumors. We analyzed both disease relapse and lymph node positivity, as they represent two critical indicators of the aggressiveness of the disease. To do so, we grouped patients based on established outcomes and surveyed for difference in BCAR3 expression between groups. In a cohort of patients with ER+ breast tumors treated with endocrine therapy for 5 years (NCBI-GEO GDS807) 30 , those who developed disease relapse had lower levels of BCAR3 expression in their primary tumors ( Figure 1G ) and lower BCAR3 transcript abundance (data not shown). These results, together with Kaplan-Meier analysis, highlight a high degree of overlapping between patients with low BCAR3 levels and patients with disease relapse. Additionally, using the ROCK breast cancer functional genomics database 31 , from a CGH dataset designed to identify copy number abnormalities in breast cancer 32 , we clearly established a correlation between advanced Tumor N-stage/lymph node status and loss of heterozygosity at BCAR3 alleles in breast cancer patients,. Particularly, combined loss and deletion of BCAR3 alleles increased from 18% in N0 tumors (no lymph node invasion), to 31% in N1 tumors (tumor cells in regional lymph nodes), and to 50% in N2 tumors (tumor cells in regional and distant lymph nodes). Altogether, these results indicate that loss of BCAR3 expression correlates with an invasive tumor phenotype, increased lymph node involvement. Concomitantly, high BCAR3 expression levels are predictive of significantly improved progression-free, distant metastasis free and relapse free survivals. Our data also suggest that BCAR3 likely plays a tumor suppressor-like role by preventing disease progression in breast cancer patients, independently of treatments received.
BCAR3 antagonizes TGFβ-induced Smad phosphorylation and nuclear translocation.
We then sought to investigate the molecular mechanisms by which BCAR3 exerts this protective role in breast cancer cells. Interestingly, a BCAR3-interacting protein, p130Cas, was previously shown to directly interact with Smad2/3, thereby blocking Smad C-terminal serine phosphorylation and activation, resulting in an inhibition of TGFβ signaling 33, 34 . As the TGFβ/Smad signaling pathway has been shown to play a prominent role in breast cancer progression and tumor metastasis, we investigated whether BCAR3 could regulate TGFβ/Smad signal transduction. We initially examined the relative protein expression levels of BCAR3 and p130Cas in a panel of breast cancer cell lines representing different molecular subtypes and phenotypes of breast tumors.
Similar to previously reported findings 35 , we found that BCAR3 expression level was relatively high in estrogen-independent breast cancer cells ( Fig.2A) . Additionally, BCAR3 expression generally correlated with breast cancer subtype. Luminal-like MCF-7
and SK-BR-3 cells express relatively low levels of BCAR3, whereas basal-like MDA-MB-231, SCP2, BT-549 and SUM-149PT cells expressed relatively high levels of BCAR3 ( Fig.2A) . However, SUM-159PT cells, which are ER-and estrogen-independent in culture and as xenograft, also expressed a relatively low level of BCAR3 ( Fig. 2A ).
This may likely be due to the anaplastic nature of the origin of these cells 36 . Furthermore, p130Cas is fairly abundant in all cells tested, and its expression did not seem to correlate with either ER status or cancer subtype ( Fig.2A) . These results suggest that while p130Cas expression maybe a universal event in most types of breast cancer cells and tumors, high BCAR3 expression is likely specific in cells of a basal like breast cancer phenotype.
We used both loss-of-function and gain-of-function approaches to investigate whether BCAR3 is involved in regulating the TGFβ/Smad signaling axis in breast cancer cells. SCP2 cells were derived as a sub-progeny of MDA-MB-231 cells, and are highly invasive and highly responsive to TGFβ 26, 37 . Moreover, these cells express high levels of BCAR3 among the panel of breast cancer cell lines that we tested ( Fig.2A) . In SCP2 cells, TGFβ induced Smad3 phosphorylation in time dependent manner, however, this effect was markedly potentiated when BCAR3 gene expression was silenced, using a specific siRNA, suggesting that BCAR3 is inhibitory to TGFβ and Smad signaling (Fig.2B ) .
To further address this inhibitory role, we examined the effect of ectopic BCAR3 on Smad signaling in MCF7 cells, which express fairly low or undetectable endogenous BCAR3 levels. We used an inducible stable MCF-7 cell line that overexpresses BCAR3 under the control of a tet-off promoter under normal culture conditions 7 . As shown in We also investigated the effect of BCAR3 overexpression on TGFβ signaling using fluorescent confocal microscopy. We transiently over expressed FLAG-tagged AND-34 (the mouse homologue of BCAR3) in SUM-159-PT cells, which express low endogenous BCAR3 levels. This allowed us to observe both cells overexpressing BCAR3 and nonoverexpressing cells in the same field ( Fig.2E ). Interestingly, cells expressing FLAG-AND-34/BCAR3 displayed weaker overall phospho-Smad3 signals, compared to nontransfected cells in the same field, under both resting and TGFβ stimulated conditions ( Fig.2E ). We further quantified Smad3 phosphorylation levels in 5 original confocal images for each experimental condition. As shown in Fig.2F , TGFβ-induced Smad3 phosphorylation was remarkably impaired in cells overexpressing BCAR3, further confirming the results obtained by immunoblot analysis ( Fig.2A-D) .
BCAR3 inhibits TGFβ-mediated Smad transcriptional activity and target gene expression.
We then investigated whether modulating BCAR3 levels could alter Smad-mediated transcriptional activity using a Smad-responsive reporter construct, 12CAGA-lux, which These cells retain partial cytostatic response to TGFβ. We therefore investigated whether ectopic BCAR3 could antagonize TGFβ's growth inhibitory effects in these cells. Stable MCF-7 cells cultured with doxycycline expressed low level of BCAR3. TGFβ treatment resulted in 25% reduction in cell viability, as determined by an MTT cell viability assay.
Stable BCAR3 expression, on the other hand, reversed TGFβ's effect, resulting in less than 10% reduction in cell viability (Fig.3D ). As such, ectopic BCAR3, through inhibition of Smad-mediated transcriptional activity, also inhibits Smad-dependent cytostatic effects.
BCAR3 antagonizes TGFβ's pro-migratory and pro-invasive responses.
A hallmark effect of TGFβ in breast cancer cells, particularly in basal-like and triplenegative cells, is single cell migration 17, 26, 42, 43 . Lines of evidence suggest that TGFβ reprograms transcriptional profiles in breast cancer cells to induce epithelial to mesenchymal transition, formation of filopodia, and switching from collective cell migration to single cell migration and ultimately to facilitate intravasation 26, 42, 44, 45 . These effects, although not necessarily concomitant, highlight the pro-migratory role of TGFβ.
As such, we investigated whether modulating BCAR3 levels in basal-like breast cancer cells could affect TGFβ-induced cell migration. For this, we silenced endogenous BCAR3 gene in SCP2 cells using 2 specific siRNAs, and examined TGFβ-induced cell migration using the Incucyte time-lapse video imaging migration assay, as previously described 26 . This method couples wound-healing assay with quantitative imaging, and present cell migration by relative wound density, which is the real-time ratio between cell densities within the initial wound area to cell density of adjacent, non-wounded area. As such, this method precludes a net change in cell number over time due to cell proliferation.
TGFβ induced time-dependent migration of SCP2 cells (Fig.4A and Fig.4B ). The effect was detectable as early as 12 hrs following stimulation of the cells and further increased over time to reach a plateau at 48 hours. Cell density in the wounded area is slightly over 52% of that of the adjacent area. TGFβ treatment resulted in an about 10% increase in relative cell density, indicative of more cells in the wounded area. Individual siRNAs against BCAR3 decreased cell migration; marked by only about 42% increase in relative wound density after 48 hours (Fig.4A) . This is consistent with previous findings that ectopic BCAR3 expression increases cell migration 9 . Interestingly, cells transfected with the siRNAs displayed an increased response to TGFβ, marked by about 15% increase in relative cell density (Fig. 4A ). The 2 siRNA constructs seemed to have similar effects. As such, these data indicate that endogenous BCAR3 is an antagonistic molecule of TGFβinduced cell migration.
Single cell migration requires actin being organized into treadmilling filaments oriented toward lamilipodia 46 . As such, we investigated whether ectopic BCAR3 expression could antagonize TGFβ's effects on the formation of these structures in SUM-159-PT cells, since these cells express a low level of endogenous BCAR3. Cells were transiently transfected with the FLAG-AND34 (BCAR3) cDNA to allow for the examination of both positive and negative BCAR3 overexpressing cells in the same field. In the absence of BCAR3 overexpression, TGFβ induced a network of elongated actin stress fibers aligned toward filopodia-like structures, indicative a pro-migratory phenotype (Fig.4C, white arrows). In contrast, cells overexpressing BCAR3, although still contained actin filaments, failed to display dominant filopodia-like structures. Rather, they contained relatively short, branched fibers that oriented towards all directions, even when they were stimulated with TGFβ ( Fig.4C, yellow arrows) . We observed these phenotypes with virtually all transfected cells. Taken together, these data demonstrate that BCAR3 could antagonize TGFβ's pro-migratory function, likely by interfering with TGFβ-mediated actin filament rearrangement and filopodia formation.
Digestion of extracellular matrix is both a major event during cell invasion and an
indication of aggressive property of cancer cells. TGFβ acts as a potent pro-invasive factor in breast cancer and it was previously that this growth factor could increase digestion of a gelatin matrix by MDA-MB-231 cells, using a matrix degradation assay 47 .
As such, we investigated whether endogenous BCAR3 could antagonize the TGFβ's proinvasive effects. As shown in Fig. 5 , mock-transfected and control siRNA transfected MDA-MB-231 displayed low of invasive properties under basal conditions. Indeed, when plated on coverslips coated with Alexa488-tagged gelatin, these cells produced small and scattered areas of digestion underneath their bodies, observed as dark spots under confocal microscope (as indicated by the yellow arrows in Fig. 5A ). Under these conditions, mock transfected and control siRNA transfected MDA-MB-231 cells treated with TGFβ displayed a clear increase in the total area of digested matrix ( Fig. 5A and 5B ).
Many of these digested areas were elongated, indicative of cell movement during matrix digestion (Fig. 5A) . Noticeably, instead of scattering underneath the cell body, elongated digestion spots tend to aggregate at the cell protrusions, overlapping with the lamilipodialike structures formed by bundled actin filaments (white arrows). These data suggest that in addition to increasing digestion of gelatin matrix, TGFβ also affects the localization of the invadopodia in MDA-MB-231 cells, and remodels their structure from a scattered to an aggregated pattern. Interestingly, transfection of MDA-MB231 cells with a pool of BCAR3 siRNAs significantly potentiated TGFb's effects on matrix digestion, as illustrated by the large areas of digested gelatin (Fig.5A) . Particularly, these areas were formed by multiple elongated spots roughly parallel to each other's. These spots also appeared to be longer than those formed in control cells. Efficiency of the siRNA knockdown was verified by Western blotting, as shown in Fig.5C . Taken together, these results indicate that BCAR3 gene silencing, by means of RNA interference, potentiates TGFβ-induced invadopodia activity and matrix digestion, strongly suggesting that endogenous BCAR3 inhibits TGFβ-induced invadopodia remodeling and matrix digestion.
BCAR3 requires p130Cas to antagonize Smad signaling.
Previous studies indicated that the p130Cas physically interacts with Smad2/3 and antagonize Smad activation 33, 34 . As p130Cas also interacts with BCAR3, this prompted us to investigate whether p130Cas is involved in BCAR3-mediated inhibition of TGFβ/Smad signaling. Using co-immunoprecipitation analysis in SCP2 cells, we found p130Cas to be constitutively associated with Smad2/3 (Fig.6A ). However, knocking down endogenous BCAR3 expression, by means of RNA interference, effectively impaired this association, suggesting that endogenous BCAR3 promotes the interaction between p130Cas and Smad2/3 (Fig.6A ).
We next investigated if BCAR3 also required p130Cas to modulate TGFβ-induced cell migration. Transfecting cells with siRNAs targeting BCAR3 and p130Cas both decreased basal cell migration, and increased TGFβ-induced cell migration (not shown and Fig. 6B , respectively). However, upon silencing p130Cas, BCAR3 siRNA lost the effect to further potentiate TGFβ-induced cell migration (Fig. 6C) . Indeed, TGFβ stimulation resulted in about 40% increase in cell migration in mock-transfected cells at 36 hours poststimulation. Transfecting cells with BCAR3 siRNA, or p130Cas siRNA, or both, all resulted in about 70% increases. Co-transfection of the 2 siRNAs did not have a morethan-additive effect (Fig. 6D ), suggesting that BCAR3 requires the presence of p130Cas to antagonize TGFβ function. Altogether, these data suggest that BCAR3 modulates an interaction between p130Cas and Smad2/3, thereby blocking TGFβ /Smad-mediated cell migration.
6. BCAR3 mediates a positive feedback of TGFβ signaling in breast cancer cells.
Despite of extensive studies on the molecular functions of BCAR3, there is no report on how BCAR3 gene expression is regulated. As cellular signaling pathways are often modulated by feedback regulatory loop mechanisms to ensure defined signaling intensity and duration, we investigated whether TGFβ signaling itself could modulate BCAR3 gene expression. For this, we stimulated a panel of breast cancer cell lines with TGFB for 24 hours, and examine the protein level of BCAR3. As shown in Fig.7A , TGFβ treatment resulted in a remarkable decrease in BCAR3 protein levels in all cell line tested, highlighting BCAR3 as a novel target for TGFβ signaling. Furthermore, our results also indicate that TGFβ-mediated suppression of BCAR3 gene expression depends on the canonical Smad2/3 signaling, as silencing either Smad2 or Smad3 gene expression in BT-549 cells using specific siRNAs in BT-549 cells almost completely abolished TGFβ's effect in decreasing BCAR3 protein expression ( Fig. 7B) . Taken together, our results define a positive feedback loop mechanism, by which TGFβ/Smad signaling transcriptionally repress expression of its own inhibitory molecule, BCAR3, further leading to enhanced TGFβ/Smad signaling in breast cancer cells (Fig. 7C) .
Discussion:
In this study, we defined a novel role for BCAR3 to antagonize the canonical TGFβ signaling by promoting an interaction between p130Cas and the Smad transcription TGFβ's cytostatic effect. These findings imply that the novel function of BCAR3 to inhibit Smad signaling is likely a conserved mechanism among the different molecular subtypes of breast cancer.
Interestingly, we found BCAR3 to be a novel target gene of TGFβ in breast cancer cells.
TGFβ decreased BCAR3 protein expression in multiple breast cancer cells. This effect appeared to be Smad-dependent, as it could be abolished by knocking down either Smad2 or Smad3. These data are the first to describe a molecular mechanism by which BCAR3 expression is being regulated. More importantly, our data define a positive feedback mechanism downstream of TGFβ/Smad signaling. It is known that a few negative feedback loops exist to fine-tune TGFβ signaling, such as those mediated by Smad7 41 and GRK2 50 . Both of these targets were shown to be being up-regulated by TGFβ, further leading to termination of Smad signaling 41, 50, 51 . To our knowledge, BCAR3 serves as the first example of a positive feedback loop of TGFβ/Smad signaling, whereby TGFβ signaling itself can decrease the expression levels of its inhibitor BCAR3, further leading to enhanced and potentiated TGFβ/Smad signaling. Such a mechanism may be important for maintaining a steady response to TGFβ.
It has been established that active Smad signaling contributes to breast cancer local invasion and distant metastasis. Having defined BCAR3 as a novel TGFβ/Smad inhibitory molecule, this may account for the low BCAR3 expression levels observed in primary breast tumors associated with worse prognosis and higher chances of disease progression. Indeed, low BCAR3 levels may release tumor cells from its inhibitory effect on Smad signaling, leading to enhanced, more potent TGFβ activity and tumor progression. Results from our clinical data survey and analysis define BCAR3 as a single factor whose expression level is predictive of clinical outcomes in breast cancer patients.
Moreover, we also found that patients with lymph node metastasis tend to carry loss of heterozygosity at BCAR3 alleles, indicating that BCAR3 has some features of a tumor suppressor-like gene to prevent disease progression. MDA-MB-231 cells were transfected with FLAG-tagged GRK2 and seeded on coverslips coated with Alexa488-labeled gelatin matrix. Cells were then stimulated with or without TGFβ for 36h, and subjected for immunofluorescence microscopy analysis.
